Skip to main content

Table 4 Relative risks of breast cancer death associated with tumor size, grade, and recurrence score among ER-positive patients, stratified by treatment with tamoxifen

From: A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

Score Cases Controls RR 95% CI P value
Tamoxifen treated (55 cases and 150 controls)
Multivariate analyses without Recurrence Score1        
   Tumor size (cm)        0.009
Continuous2 55 (100%) 150 (100%) 2.6 (1.2–5.5)  
   Grade (pathologist 1)        0.007
Well 6 (11%) 50 (33%) 1.0 reference  
Moderate 28 (51%) 69 (46%) 2.8 (1.1–7.4)  
Poor 21 (38%) 31 (21%) 4.5 (1.6–12.3)  
Multivariate analyses with Recurrence Score3
   Tumor size (cm)        0.013
Continuous2 55 (100%) 150 (100%) 2.5 (1.2–5.4)  
   Grade (pathologist 1)        0.126
Well 6 (11%) 50 (33%) 1.0 reference  
Moderate 28 (51%) 69 (46%) 2.4 (0.9–6.4)  
Poor 21 (38%) 31 (21%) 2.8 (0.9–9.3)  
   Recurrence Score        0.003
Continuous4 55 (100%) 150 (100%) 5.3 (1.6–17.2)  
Tamoxifen untreated (110 cases and 251 controls)
Multivariate analyses without Recurrence Score1
   Tumor size (cm)        0.035
Continuous2 110 (100%) 251 (100%) 1.8 (1.0–3.1)  
   Grade (pathologist 1)        <0.001
Well 17 (15%) 83 (33%) 1.0 reference  
Moderate 54 (49%) 131 (52%) 2.0 (1.1–3.6)  
Poor 39 (35%) 37 (15%) 4.7 (2.3–9.9)  
Multivariate analyses with Recurrence Score3
   Tumor size (cm)        0.036
Continuous2 110 (100%) 251 (100%) 1.8 (1.0–3.1)  
   Grade (pathologist 1)        0.018
Well 17 (15%) 83 (33%) 1.0 reference  
Moderate 54 (49%) 131 (52%) 1.8 (1.0–3.4)  
Poor 39 (35%) 37 (15%) 3.2 (1.4–7.2)  
   Recurrence Score        0.025
Continuous4 110 (100%) 251 (100%) 2.4 (1.1–5.2)  
  1. 1Conditional logistic regression models include tumor size and tumor grade only. 2Relative risks for tumor size calculated with regard to an increment of 2 cm. 3Conditional logistic regression models include tumor size, tumor grade, and Recurrence Score. 4Relative risks for Recurrence Score calculated with regard to an increment of 50 units (chosen to be consistent with and comparable to previous studies). CI, confidence interval; ER, estrogen receptor; RR, relative risk.